McKesson's Earnings Report: A Prescription for Growth in Fiscal 2026

May 8, 2025 | By Matt Levine

Introduction

In the grand theater of corporate earnings, McKesson Corporation (NYSE: MCK) has taken the stage with impressive results for its fiscal 2025 fourth quarter and full-year earnings report. The company?s latest figures not only delivered a delightful earnings surprise but also set the stage for a robust revenue forecast for fiscal 2026. With an EPS consensus that exceeded expectations, let?s dive into what this means for McKesson and its peers in the healthcare sector.

Fourth Quarter Highlights

McKesson reported consolidated revenues of a staggering $90.8 billion, reflecting a 19% increase year-over-year. This performance is no small feat, especially in an industry facing various challenges. The company?s earnings per diluted share (EPS) soared to $10.01, marking a $3.99 increase from the same quarter last year. Adjusted EPS came in even higher at $10.12, demonstrating a remarkable 64% growth.

Full Year Results: A Year of Growth

For the fiscal year, McKesson?s consolidated revenues reached $359.1 billion, a 16% jump. The annual EPS rose to $25.72, up by $3.33, while adjusted EPS climbed to $33.05, showcasing a 20% increase. The company also reported a robust cash flow from operations of $6.1 billion and free cash flow of $5.2 billion, which are crucial indicators of financial health.

Words from Leadership

Brian Tyler, McKesson?s CEO, expressed optimism in the company?s performance, attributing it to strong operational execution and strategic priorities. ?The strength of our core pharmaceutical distribution business, expansion of our Oncology platform, and continued growth of our differentiated biopharma solutions businesses led to strong results,? he stated. It seems McKesson is not just playing the game; they are rewriting the playbook.

Looking Ahead: Fiscal 2026 Guidance

As we gaze into the crystal ball that is McKesson's fiscal 2026 guidance, the company has established an adjusted EPS range of $36.75 to $37.55, indicating an anticipated growth of 11% to 14% compared to the previous year. Excluding net gains from McKesson Ventures? equity investments, the forecast points to an even more optimistic growth outlook of 13% to 16%. This sets a high bar for competitors in the healthcare space, who may need to step up their game.

Conclusion: A Bright Prescription for the Future

In summary, McKesson's impressive earnings report not only highlights its operational strengths but also suggests a promising trajectory for fiscal 2026. With an EPS that exceeded the consensus and a strong revenue forecast, McKesson is well-positioned to capitalize on the ongoing evolution in the healthcare sector. As the company focuses on its strategic priorities, it will be interesting to see how it navigates the competitive landscape ahead. Investors should keep a close eye on MCK as it continues to deliver on its growth ambitions.